🇺🇸 FDA

Intelligence Platform

Patents

Browse 29,054 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12156903

Use of ADAMTS13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sick

Takeda Pharmaceutical Company Limited · Granted Tue Dec 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12156879

Combining BACE1 inhibitors with mGluR agonists for Alzheimer's disease therapy

UNIVERSITY OF CONNECTICUT · Granted Tue Dec 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12156908

Virus like nanoparticle compositions and methods thereof

Regents of the University of Minnesota · Granted Tue Dec 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12156883

Bisphosphocin gel formulations and uses thereof

Lakewood Amedex, Inc. · Granted Tue Dec 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12156940

Manufacturing of bupivacaine multivesicular liposomes

Pacira Pharmaceuticals, Inc. · Granted Tue Dec 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12156912

Methods and compositions for inhibiting diseases of the central nervous system

BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Tue Dec 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12156862

Medicaments for the treatment of vasoconstriction related diseases or disorders

Sulfateq B.V. · Granted Tue Dec 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12156870

Antibody drug conjugates comprising sting agonists

Mersana Therapeutics, Inc. · Granted Tue Dec 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12156914

Pharmaceutical compositions comprising bupropion and cysteine

AXSOME THERAPEUTICS, INC. · Granted Tue Dec 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12156931

Organic counteranion co-assembly strategy for the formation of cyclodextrin-containing hyb

Northwestern University · Granted Tue Dec 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12157762

Tethered interleukin-15 and interleukin-21

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Dec 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12157778

Peptides for activation of cell signaling in osteoprogenitor cells

The Regents of the University of California · Granted Tue Dec 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12157891

Treatment of uveitis with endoplasmic reticulum aminopeptidase 1 (ERAP1) inhibitors

REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12152262

PH20 polypeptide variants, formulations and uses thereof

HALOZYME, INC. · Granted Tue Nov 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12152270

Neurotransmitter transport in probiotics

Regents of the University of Minnesota · Granted Tue Nov 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12152244

Selective antisense compounds and uses thereof

Ionis Pharmaceuticals, Inc. · Granted Tue Nov 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12152007

Substituted heterocycles as c-MYC targeting agents

Northwestern University · Granted Tue Nov 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12152242

CRISPR therapy

The Government of the United States of America as represented by the Secretary of the Deptartment of Health and Human Services · Granted Tue Nov 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12152038

Vasopressin receptor antagonists and products and methods related thereto

Neumora Therapeutics, Inc. · Granted Tue Nov 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12152061

T-cell modulatory multimeric polypeptides and methods of use thereof

Cue Biopharma, Inc. · Granted Tue Nov 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12152067

Human antibodies to ebola virus glycoprotein

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12152034

FGFR inhibitors and methods of making and using the same

Relay Therapeutics, Inc. · Granted Tue Nov 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12151998

Solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N′-((1-(4-(dimethylamino)phenyl)cyclop

THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Nov 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12152028

Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators

Corcept Therapeutics Incorporated · Granted Tue Nov 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted